| Literature DB >> 35416779 |
Valerie Chua1, Jin Hean Koh1, Choon Huat Gerald Koh1, Shilpa Tyagi1.
Abstract
BACKGROUND: Telemedicine is increasingly being leveraged, as the need for remote access to health care has been driven by the rising chronic disease incidence and the COVID-19 pandemic. It is also important to understand patients' willingness to pay (WTP) for telemedicine and the factors contributing toward it, as this knowledge may inform health policy planning processes, such as resource allocation or the development of a pricing strategy for telemedicine services. Currently, most of the published literature is focused on cost-effectiveness analysis findings, which guide health care financing from the health system's perspective. However, there is limited exploration of the WTP from a patient's perspective, despite it being pertinent to the sustainability of telemedicine interventions.Entities:
Keywords: chronic disease; mobile phone; patients; systematic review; telemedicine; willingness to pay
Mesh:
Year: 2022 PMID: 35416779 PMCID: PMC9047785 DOI: 10.2196/33372
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 7.076
Summary of included studies (N=11).
| Study | Country | Year | Eligibility | Sample size, n | Intervention | Measurement method for WTPa | Patients willing to pay | WTP | Standardized WTP (US $ in 2021) |
| Bradford et al [ | United States | HTNb clinical study (1999-2000), CHFc clinical study (2000-2001) | Patients were recruited from a HTN and CHF study; eligibility criteria was not stated | 34 | Telemedicine for HTN: peripherals send information on blood pressure, temperature, weight, heart function, and so on. Telemedicine under CHF: weight scale, blood pressure monitor, pulse oximeter, stethoscope, handheld ECGd, and a base PC platform | CVMe | At US $29.96, 32% of the population with HTN would pay out of pocket to access telemedicine. At US $29.96, >45% of the population with CHF would be willing to pay out of pocket for telemedicine access | The dollar amount when randomly varied among patients had a normal distribution with a US $20 mean (per visit) | US $29.96 per visit |
| Bettiga et al [ | Italy | N/Af,g (paper’s year of publication will be used as a reference for currency standardization) | Healthy patients without HTN | 350 | Mobile health technologies that are connected to the internet and made accessible via smartphones | Survey | N/A | N/A | N/A |
| Fletcher et al [ | United Kingdom | June 3-20, 2016 | Patients with self-reported HTN who were aged ≥18 years | 212 | Telemedicine for HTN management | DCEh | N/A | A total of €374.74 (US $414.76), €398.98 (US $441.59), and €673.45 (US $745.37) for a 10%, 15%, and 25% reduction in 5-year cardiovascular disease risk, respectively | US $456.99, US $486. 55, and US $821.25 for a 10%, 15%, and 25% reduction in 5-year cardiovascular disease risk, respectively |
| Losiouk et al [ | Italy | A clinical trial conducted in 2015 | Participants in the baseline and poststudy questionnaire were parents of children with diabetes | 167 | Web-based telemonitoring service that allowed parents to oversee their child | Questionnaire | N/A | Median WTP of €200 (US $265.68) annually | Median of US $246.40 annually |
| Park et al [ | South Korea | Patients were surveyed from October to November 2009. Physicians were surveyed in January 2010. | Patients surveyed visited outpatient clinics at 2 tertiary care hospitals for diabetes | 41 | Telemedicine for diabetes management | Conjoint analysis | N/A | Marginal WTP for comprehensiveness of service is ₩16,957 (US $15.26) monthly. WTP for mobile phone over internet-based medical services is ₩15,899 (US $14.31) monthly. WTP for general hospital over physician-based services is ₩15,143 (US $13.63) monthly | US $18.43 monthly for service comprehensiveness. US $17.27 monthly for mobile phone over internet-based services. US $16.46 monthly for general hospital over physician-based services |
| Snoswell et al [ | Australia | N/Ai | Voluntary participants from the SKINj Research Project RCTk were included if they owned or could access an iPhone compatible with the study’s dermoscopic attachments. Participants were excluded if in the last 5 years, they were diagnosed with melanoma | 118 | Direct-to-consumer teledermoscopy, which allows patients to interact directly with their dermatologists | DCE | N/A | Marginal WTP of Aus $1.18 (US $0.88) to switch from a GPl visitation to mobile teledermoscopy; WTP of Aus $43 (US $32.14) to switch from a GP to a dermatologist; WTP of Aus $117 (US $87.46) to switch to an increased chance of melanoma detection | Marginal WTP of US $0.89 to switch from a GP visitation to mobile teledermoscopy; WTP of US $32.25 to switch from a GP to a dermatologist; WTP of US $87.75 to switch to an increased chance of melanoma detection |
| Bergmo and Wangberg [ | Norway | The RCT was conducted from 2002 to 2003 | The study’s participants were aged ≥18 years who had internet access and were keen on communicating with their GP electronically | 151 | Intervention groups were given access to an electronic communication system for communication with their GP | Questionnaire | Of participants, 51% expressed a positive WTP, 21% expressed a WTP of 0, and 28% declined to answer | The mean WTP for the intervention group is €4.52 (US $5.11), whereas that of the control group is €6.78 (US $7.66). WTP are expressed per web-based consultation session | The intervention group has a mean WTP of US $7.36, and the control group has a mean WTP of US $11.04 |
| Scherrenberg et al [ | Belgium | July to August 2020 | Patients From Jessa Hospital | 93 | Remote cardiac rehabilitation exposure via telephone, video consultations. or live exercise | DCE | Of patients, 70% were willing to pay as much for telerehabilitation as center-based CRm | N/A | N/A |
| Ramchandran et al [ | United States | 2017 | Participants had diabetes, had to be cognitively and medically fit to be interviewed or participate in the focus group held in English. Participants had to have a dilated eye examination, be assessed through teleophthalmology, or did not visit an eye physician in the past 2 years | 23 | Teleophthalmology, which utilizes a camera-based retinopathy exam in noneye care settings for remote image assessment | Survey | Of patients, >50% indicated their WTP to be US $32.38 or US $43.18 | WTP was the amount patients usually copay (not stated) | Of patients, >50% indicated their WTP to be US $32.38 or US $43.18 |
| Spinks et al [ | Australia | N/An | To be included, participants had to be aged 50-64 years, reside in Queensland, and have moderate or high melanoma risk | 35 | Teledermoscopy images for review by teledermatologists | DCE | N/A | Participants had a WTP of Aus $110 (US $101.20) to move from choosing between SSEo, skin cancer clinic, and GP screening to a scenario where teledermoscopy and dermatologists are offered | Participants had a WTP of US $89.70 to move from choosing between SSE, skin cancer, clinic and GP screening to a scenario where teledermoscopy and dermatologists are offered |
| Bradford et al [ | United States | Clinical trial conducted from 2000 to 2001. | Patients with CHF discharged from CHF-relevant inpatient stays | 126 | A PC-dependent system that collected clinical data for care and monitoring of patients with CHF | DBDCp CVM | Of patients, 55% had a WTP of US $29.96 for telemedicine rather than in-person care at the physician’s office. Of patients, 19% had a WTP of US $59.91 for telemedicine rather than in-person care at the physician’s office | WTP of US $20 and US $40 per visit | WTP of US $29.96 and US $59.91 per visit |
aWTP: willingness to pay.
bHTN: hypertension.
cCHF: chronic heart failure.
dECG: electrocardiogram.
eCVM: contingent valuation method.
fN/A: not applicable.
gThe paper’s year of publication in 2020 will be cited as the year in which the study is conducted, as the time frame for when the intervention was conducted was not provided.
hDCE: discrete choice experiment.
iThe paper’s year of publication in 2018 will be cited as the year in which the study was conducted, as the year of study was not reported in the paper.
jSKIN: Skin Innovation.
kRCT: randomized control trial.
lGP: general practitioner.
mCR: cardiac rehabilitation.
nThe paper’s year of publication in 2016 will be cited as the year in which the study was conducted, as the year of study was not reported in the paper.
oSSE: skin self-examination.
pDBDC: double-bounded dichotomous choice.
Factors associated with WTPa in the included studies.
| Study | Demographics | Socioeconomic income | Health service distance to preferred health facility | |||||
|
| Gender (female) | Age | Married | Ethnicity |
|
| ||
| Bradford et al [ | +b | −−c | −d | − | + | ++e | ||
| Bettiga et al [ | N/Af | N/A | N/A | N/A | N/A | N/A | ||
| Fletcher et al [ | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Losiouk et al [ | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Park et al [ | N/A | −− | N/A | N/A | N/A | N/A | ||
| Snoswell et al [ | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Bergmo and Wangberg [ | N/A | ++ | N/A | N/A | + | N/A | ||
| Scherrenberg et al [ | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Ramchandran et al [ | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Spinks et al [ | N/A | N/A | N/A | N/A | N/A | N/A | ||
| Bradford et al [ | + | −− | − | + | + | ++ | ||
aWTP: willingness to pay.
bThe effect of the variable is positive and nonsignificant.
cThe effect of the variable is negative and significant.
dThe effect of the variable is negative and nonsignificant.
eThe effect of the variable is positive and significant.
fN/A: not applicable; the effect of the variable is not applicable to this study.
Quality appraisal of the included studies.
| Question | Bradford et al [ | Bettiga et al [ | Fletcher et al [ | Losiouk et al [ | Park et al [ | Snoswell et al [ | Bergmo and Wangberg [ | Scherrenberg et al [ | Ramchandran et al [ | Spinks et al [ | Bradford et al [ |
| 1. Did the study address a clearly focused question or issue? | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 2. Is the research method (study design) appropriate for answering the research question? | Yes | Yes | Yes | Yes | Yes | Yes | Cannot tell | Yes | Cannot tell | Yes | Yes |
| 3. Is the method for the selection of the participants (employees, teams, divisions, and organizations) clearly described? | Cannot tell | Cannot tell | Yes | Cannot tell | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 4. Could the way the sample was obtained introduce (selection) bias | Cannot tell | Cannot tell | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| 5. Was the sample of participants representative with regard to the population to which the findings will be referred? | Cannot tell | Cannot tell | Cannot tell | No | Yes | Yes | Yes | Cannot tell | Yes | Yes | Yes |
| 6. Was the sample size based on prestudy considerations of statistical power? | No | No | No | No | No | No | No | No | No | Yes | No |
| 7. Was a satisfactory response rate achieved? | Cannot tell | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No | No |
| 8. Are the measurements (questionnaires) likely to be valid and reliable? | Yes | Yes | Yes | No | Yes | Yes | No | No | Yes | No | Yes |
| 9. Was the statistical significance assessed? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes |
| 10. Are CIs given for the main results? | No | No | Yes | No | No | Yes | Yes | No | No | Yes | No |
| 11. Could there be confounding factors that have not been accounted for? | No | Yes | No | Yes | Yes | No | Cannot tell | No | Yes | Yes | Yes |
| 12. Can the results be applied to your organization? | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |